The Journal of Allergy and Clinical Immunology
Volume 117, Issue 1 , Pages 3-16 , January 2006

Is there a problem with inhaled long-acting β-adrenergic agonists?

  • Harold S. Nelson, MD

      Affiliations

    • Corresponding Author InformationReprint requests: Harold S. Nelson, MD, National Jewish Medical and Research Center, 1400 Jackson St, Denver, CO 80206.

Received 26 September 2005 ,Revised 5 October 2005 ,Accepted 7 October 2005.

References 

  1. Stolley PD, Schinnar R. Association between asthma mortality and isoproterenol aerosols: a review. Prev Med. 1978;7:519–538
  2. Pearce N, Beasley R, Crane J, Burgess C, Jackson R. End of the New Zealand asthma mortality epidemic. Lancet. 1995;345:41–44
  3. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, et al. The use of β-agonists and the risk of death and near death from asthma. N Engl J Med. 1992;326:501–506
  4. Suissa S, Ernst P, Boivin J-F, Horwitz RI, Habbick B, Cockcroft D, et al. A cohort analysis of excess mortality in asthma and the use of inhaled β-agonists. Am J Respir Crit Care Med. 1994;149:604–610
  5. Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J. 1994;7:1602–1609
  6. Blais L, Ernst P, Suissa S. Confounding by indication and channeling over time: the risks of beta2-agonists. Am J Epidemiol. 1996;144:1161–1169
  7. Garrett JE, Lanes SF, Kolbe J, Rea HH. Risk of severe life threatening asthma and beta agonist type: an example of confounding by severity. Thorax. 1996;51:1093–1099
  8. Garrett J, Kolbe J, Richards G, Whitlock T, Rea H. Major reduction in asthma morbidity and continued reduction in asthma mortality in New Zealand; what lessons have been learned?. Thorax. 1995;50:303–311
  9. Sears MR, Taylor DR, Print CG, Lake DC, Li QO, Flannery EM, et al. regular inhaled B-agonist treatment in bronchial asthma. Lancet. 1990;336:1391–1396
  10. Drazen JM, Israel E, Boushey HA, Chinchilli VA, Fahy JE, Lazarus SC, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. N Engl J Med. 1996;335:841–847
  11. Dennis SM, Sharp SJ, Vickers MR, Frost CD, Crompton GK, Barnes PJ, et al. Regular inhaled salbutamol and asthma control: the TRUST randomized trial. Lancet. 2000;355:1675–1679
  12. Pearlman D, Chervinsky P, LaForce C, Seltzer JM, Southern DL, Kemp JP, et al. A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma. N Engl J Med. 1992;327:1420–1425
  13. D'Alonzo GE, Nathan RA, Henochowicz S, Morris RJ, Ratner P, Rennard SI. Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma. JAMA. 1994;2171:1412–1416
  14. Lipworth BJ, Struthers AD, McDevitt DG. Tachyphylaxis to systemic but not to airway responses during prolonged therapy with high dose inhaled salbutamol in asthmatics. Am Rev Respir Dis. 1989;140:586–592
  15. Weber RW, Smith JA, Nelson HS. Aerosolized terbutaline in asthmatic development of subsensitivity with log-term administration. J Allergy Clin Immunol. 1982;70:417–422
  16. Repsher LH, Anderson JA, Bush RK, Falliers CJ, Kass I, Kemp JP, et al. Assessment of tachyphylaxis following prolonged therapy of asthma with inhaled albuterol aerosol. Chest. 1984;85:34–38
  17. Nelson HS, Raine D, Doner HC, Posey WC. Subsensitivity to the bronchodilator action of albuterol produced by chronic administration. Am Rev Respire Dis. 1977;116:871–878
  18. Hancox RJ, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Taylor DR. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med. 2000;94:767–771
  19. Wahedna I, Wong CS, Wisniewski AF, Pavord ID, Tattersfield AE. Asthma control during and after cessation of regular beta2-agonist treatment. Am Rev Respir Dis. 1993;148:707–712
  20. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet. 1988;1:554–558
  21. van Schayck CP, Graafsma SJ, Visch MB, Dompeling E, van Weel C, van Herwaarden CL. Increased bronchial responsiveness after inhaling salbutamol during 1 year is not caused by subsensitization to salbutamol. J Allergy Clin Immunol. 1990;86:793–800
  22. van Schayck CP, Cloosterman SG, Bijl-Hofland ID, van den Hoogen H, Folgering HT, van Weel C. Is the increase in bronchial responsiveness or FEV1 shortly after cessation of beta2-agonist reflecting a real deterioration of the disease in allergic asthmatics patients? A comparison between short-acting and long-acting beta2-agonists. Respir Med. 2002;96:155–162
  23. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med. 1996;153:65–69
  24. Cockcroft DW, McParland CP, Britto SA, Swystun VA, Rutherford BC. Regular inhaled salbutamol and airway responsiveness to allergen. Lancet. 1993;342:833–837
  25. Cockcroft DW, O'Byrne PM, Swystun VA, Bhagat R. Regular use of inhaled albuterol and the allergen-induced late asthmatic response. J Allergy Clin Immunol. 1995;96:44–49
  26. Gauvreau GM, Jordana M, Watson RM, Cockcroft DW, O'Byrne PM. Effect of regular inhaled albuterol on allergen-induced late responses and sputum eosinophils in asthmatic subjects. Am J Respir Crit Care Med. 1997;156:1738–1745
  27. Cockcroft DW, Swystun VA, Bhagat R. Interaction of inhaled β2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med. 1995;152:1485–1489
  28. Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airways responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol. 1996;97:47–52
  29. Au DH, Lemaitre RN, Curtis JR, Smith NL, Peaty BM. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists. Am J Respir Crit Care Med. 2000;161:827–830
  30. Suissa S, Assimes T, Ernst P. Inhaled short acting beta-agonist use in COPD and the risk of acute myocardial infarction. Thorax. 2003;58:43–46
  31. Suissa S, Hemmelgard B, Blais L, Ernst P. Bronchodilators and acute cardiac death. Am J Respir Crit Care Med. 1996;154:1598–1602
  32. Au DH, Udris EM, Curtis JR, McDonell MD, Fihn SD, the ACQUIP investigators . Association between chronic heart failure and inhaled B2-adrenoceptor agonists. Am Heart J. 2004;148:915–920
  33. Poller U, Fuchs B, Gorf A, Jakubetz J, Radke J, Ponieke K, et al. Terbutaline-induced desensitization of human cardiac B2-adrenocepro-mediated positive inotropic effects, attenuation by ketotifen. Cardiovasc Res. 1998;40:211–222
  34. Sengstock DM, Obeidat O, Pasnoori V, Mehra P, Sandberg KR, McCullough PA. Asthma, B-agonists and development of Congestive heart failure: results of the ABCHF study. J Card Fail. 2002;8:232–238
  35. Taylor DR, Town GI, Herbison GP, Boothman-Burell D, Flannergy EM, Hancox B, et al. Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol. Thorax. 1998;53:748–752
  36. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, et al. The effect of polymorphisms of the b2 adrerngic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162:75–80
  37. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomized, placebo-controlled cross-over trial. Lancet. 2004;364:1505–1512
  38. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term β agonist use: influence of β2 adrenoceptor polymorphism. Thorax. 2000;55:762–767
  39. Johnson M, Butchers Pr, Colman RA, Nials AT, Strong P, Sumner MS, et al. The pharmacology of salmeterol. Life Sci. 1993;52:2131–2143
  40. Anderson GP. Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective β2 adrenoceptor agonist bronchodilator. Life Sci. 1993;52:2145–2160
  41. Fitzgerald JM, Chapman KR, Della Cioppa G, Stubbing D, Fairbarn MS, Till D. Sustained bronchoprotection, bronchodilation, and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol. 1999;103:427–434
  42. Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiselev P, et al. A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001;86:19–27
  43. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). BMJ. 2000;320:1368–1373
  44. O'Byrne PM, Barnes PJ, Rodriquez-Rotsin R, Runnerstrom R, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164:1192–1197
  45. Nelson HS, Chapman KR, Pyke SD, Johnson M, Pritchard JN. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers. J Allergy Clin Immunol. 2003;112:29–36
  46. Stoloff SW, Stempel DA, Mayer J, Stanford RH, Rosenzwseig JRC. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol. 2004;113:245–251
  47. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJH, Pauwels RA, et al. Can guideline-define asthma control be achieved? The gaining optimal asthma control study. Am J Respir Crit Care Med. 2004;170:836–844
  48. Pauwels R, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET). N Engl J Med. 1998;338:1405–1411
  49. Fitzgerald JM, Chapman KR, Della Cioppa GB, Stubbing D, Fairbarn MS, Till MD, et al. Sustained bronchoprotection, bronchodilation and symptom control during regular formoterol use in asthma of moderate or greater severity. J Allergy Clin Immunol. 1999;103:427–435
  50. Bensch G, Lapidus RJ, Levine BE, Lumry W, Yegen U, Kiseley P, et al. randomized, 12-week, double-blind placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler. Ann Allergy Asthma Immunol. 2001;86:19–27
  51. Newnham DM, Grove A, McDevitt DG, Lipworth BJ. Subsensitivity of bronchodilator and systemic beta-2 adrenoceptor responses after regular twice-daily treatment with eformoterol dry powder in asthmatic patients. Thorax. 1995;50:475–504
  52. Britton MG, Earnshaw JS, Palmer JBD. A twelve month comparison of salmeterol with salbutamol in asthmatic patients. Eur Respir J. 1992;5:1062–1067
  53. van der Woude HJ, Winter TH, Aalbers R. Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting β2 agonists. Thorax. 2001;56:529–535
  54. Jones SL, Cowan JO, Flannery EM, Hancox RJ, Herbison GP, Taylor DR. Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol. Eur Respir J. 2001;17:368–373
  55. Haney S, Hancox . Rapid onset of tolerance to beta-agonist bronchodilation. Respir Med. 2005;99:566–571
  56. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients. Lancet. 1995;348:201–206
  57. Nelson HS, Berkowitz RB, Tinkelman DA, Emmett AH, Rickard KA, Yancey SW. lack of subsensitivity to albuterol after treatment with salmeterol in patients with asthma. Am J Respir Crit Care Med. 1999;159:1556–1561
  58. Langley SJ, Masterson CM, Batty EF, Woodcock A. Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo. Eur Respir J. 1998;11:1081–1085
  59. Korosec M, Novak RD, Myers E, Skowronski M, McFadden ER. Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma. Am J Med. 1999;107:209–213
  60. Ullman A, Hedner J, Svedmyr N. In haled salmeterol and salbutamol in asthmatic patients. Am Rev Respir Dis. 1990;142:571–575
  61. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular formoterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med. 1995;152:1170–1174
  62. Booth H, Fishwick K, Harkawat R, Devereux G, Hendrick DJ, Walters EH. Changes in methacholine induced bronchoconstriction with the long acting β2 agonist salmeterol in mild to moderate asthmatic patients. Thorax. 1993;48:1121–1124
  63. Boulet L-P, Chakir J, Milot J, Boutet M, Laviolette M. Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma. Clin Exp Allergy. 2001;31:430–437
  64. Cheung D, Timmers MC, Zwinderman AH, Bel EH, Dijkman JH, Sterk PJ. long-term effects of a long-acting β2 adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. N Engl J Med. 1992;327:1196–1203
  65. Kalra S, Swystun VA, Bhagat R, Cockcroft DW. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol. Chest. 1996;109:953–956
  66. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduce protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med. 1994;88:363–368
  67. Garcia R, Guera P, Feo F, Galindo PA, Gomez E, Borja J. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. J Invest Allergol Clin Immunol. 2001;11:176–182
  68. Simons FE, Gerstner TV, Cheung MS. Tolerance to the bronchoprotective effects of salmeterol in adolescent with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99:655–659
  69. Edelman JM, Turin JA, Bronsky EA, Grossman J, Kemp JP, Ghannam AT, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. Ann Intern Med. 2000;132:97–104
  70. Burgess C, Ayson M, Rajasingham S, Crane J, Della Cioppa G, Till MD. The extrapulmonary effects of increasing doses of formoterol in patients with asthma. Eur J Clin Pharmacol. 1998;54:141–147
  71. Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C. Cardiovascular safety of salmeterol in COPD. Chest. 2003;123:1817–1824
  72. Martin RM, Dunn NR, Freemantle SN, Mann RD. Risk of non-fatal cardiac failure and ischemic heart disease with long-acting beta2 agonists. Thorax. 1998;53:558–572
  73. Dorinsky PM, Yancey S, Baitinger L, Edwards L, Sutton L, Klotsman M, et al. Salmeterol response is not effected by beta2-adrenergic receptor genotype in patients with persistent asthma. Chest 204;126(suppl):722S.
  74. Dorinsky P, Yancey S, Edwards L, Sutton L, Ortega H. Rates of asthma exacerbations are not effected by beta2-adrenergic receptor genotype in patients with persistent asthma. J Allergy Clin Immunol. 2005;115(suppl 1):S6
  75. Kraft M, Wenzel SE, Betting CM, Martin RJ. The effect of salmeterol on nocturnal symptoms, airway function and inflammation in asthma. Chest. 1997;111:1249–1254
  76. Roberts JA, Bradding P, Britten KM, Walls AF, Wilson S, Gratziou C, et al. The long-acting beta2-agonist salmeterol xinafoate: effects on airway inflammation in asthma. Eur Respir J. 1999;14:275–282
  77. Orsida BE, Ward C, Li X, Bish R, Wilson JW, Thien F, et al. Effect of a long-acting β2 agonist over three months on airway wall vascular remodeling in asthma. Am J Respir Crit Care Med. 2001;164:117–121
  78. Wallin A, Sandstrom T, Soderberg M, Howarth P, Lundback B, Della-Cioppa G, et al. The effect of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma. Am J Respir Crit Care Med. 1999;159:79–86
  79. Jeffery PK, Venge P, Gizycki MJ, Egerod I, Dahl R, Faourschou P. Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study. Eur Respir J. 2002;20:1378–1385
  80. Kips JC, O'Connor BJ, Inman MD, Svensson K, Pauwels RA, O'Byrne PM. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma. Am J Respir Crit Care Med. 2000;161:996–1001
  81. Li X, Ward C, Thien F, Bish R, Bamford T, Bao X, et al. An anti-inflammatory effect of salmeterol, a long-acting beta2 agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma. Am J Respir Crit Care Med. 1999;160:1493–1499
  82. Wallin Am Sue-Chu M, Bjermer I, Ward J, Sandstrom T, Lindberg A, et al. Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma. J Allergy Clin Immunol. 2003;112:72–78
  83. National Institutes of Health, National Heart, Lung and Blood Institute . Guidelines for the diagnosis and management of asthma: update on selected topics 2002. J Allergy Clin Immunol. 2002;110(suppl):S141–S219
  84. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Sorkness CA, et al. Long-acting B2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA. 2001;285:2583–2593
  85. Simons FE. A comparison of beclomethasone, salmeterol and placebo in children with asthma. N Engl J Med. 1997;337:1659–1665
  86. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol. Compared with beclomethasone in children with asthma. Am J Respir Crit Care Med. 1997;156:688–695
  87. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma. Am J Respir Crit Care Med. 1998;158:924–930
  88. Campbell DA, McLennan G, Coates JR, Frith PA, Gluyas PA, Latimer KM, et al. A comparison of asthma deaths and near-fatal asthma attack in South Australia. Eur Respir J. 1994;7:490–497
  89. Matz J, Emmett A, Rickard K, Kalberg C. Addition of salmeterol to low-dose fluticasone versus higher-dose fluticasone: an analysis of asthma exacerbations. J Allergy Clin Immunol. 2001;107:783–789
  90. Pace E, Gagliardo R, Melis M, La Grutta S, Ferraro M, Siena L, et al. Synergistic effects of fluticasone propionate and salmeterol on in vitro T-cell activation and apoptosis in asthma. J Allergy Clin Immunol. 2004;114:1216–1223
  91. Baraniuk J, Ali M, Brody D, Maniscalco J, Gaumond E, Fitzgerald T, et al. Glucocorticoids induce beta2-adrenergic receptor function in human nasal mucosa. Am J Respir Crit Care Med. 1997;155:704–710
  92. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, et al. Ligand-independent activation of glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem. 1999;274:1005–1010
  93. Wilkinson JRW, Roberts JA, Bradding P, Holgate ST, Howarth PH. Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaled. BJM. 1992;305:931–932
  94. Clark CE, Ferguson AD, Siddorn JA. Respiratory arrests in young asthmatics on salmeterol. Respir Med. 1993;87:227–228
  95. Finkelstein FN. Risks of salmeterol. N Engl J Med. 1994;331:1314
  96. Mann RD, Kubota k, Pearce G, Wilton L. Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients. J Clin Epidemiol. 1996;49:247–250
  97. Williams C, Crossland L, Finnerty J, Crane J, Holgate S, Pearce N, et al. Case-control study of salmeterol and near-fatal attacks of asthma. Thorax. 1998;53:7–13
  98. Lanes SF, Lanza LL, Wentworth CE. Risk of emergency care, hospitalization, and ICU stays for acute asthma among recipients of salmeterol. Am J Respir Crit Care Med. 1998;158:857–861
  99. Meier CR, Jick H. Drug use and pulmonary death rates in increasingly symptomatic asthma patients in the UK. Thorax. 1997;52:612–617
  100. Anderson HR, Ayres JG, Sturdy PM, Bland JM, Butland BK, Peckitt C, et al. Bronchodilator treatment and deaths from asthma: case-control study. BMJ. 2005;330:117
  101. Castle W, Fuller R, Hall J, Palmer J. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993;306:1034–1037
  102. Mann M, Chowdhury B, Sullivan E, Nicklas R, Anthracite R, Meyer RJ. Serious asthma exacerbations in asthmatics treated with high-dose formoterol. Chest. 2003;124:70–74
  103. Wolfe J, LaForce C, Ziehmer B, Orevillo C, Till D. High-dose formoterol not associated with increased asthma exacerbations. Proc Am Thorac Soc. 2005;2:A128
  104. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The salmeterol multicenter asthma research trial (SMART): a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest; in press.

 (Supported by an unrestricted educational grant from Genentech, Inc. and Novartis Pharmaceuticals Corporation)

 Series editor: Harold S. Nelson, MD

 Disclosure of potential conflict of interest: H. Nelson has consultant arrangements with Rigels Pharmaceuticals, Protein Design Laboratories, Wyeth Pharmaceuticals, Dynavax Technologies, Altana Pharma US, AstraZeneca, Sanofi-Aventis, Astellas, Genentech/Novartis, Dey Laboratories, Curalogic, GlaxoSmithKline, Inflazyme Pharmaceuticals, Schering-Plough, and Air Pharma; has received grants from Dey Laboratories, Ivax, Rigel, Roche, Wyeth, Astellas, Altana, GlaxoSmithKline, Schering-Plough, Novartis, Medicinova, AstraZeneca, Epigenesis, Eli Lilly, and Sanofi-Aventis; and is on the speakers' bureau for GlaxoSmithKline, Pfizer, AstraZeneca, and Schering-Plough.

PII: S0091-6749(05)02268-2

doi: 10.1016/j.jaci.2005.10.013

The Journal of Allergy and Clinical Immunology
Volume 117, Issue 1 , Pages 3-16 , January 2006

Article Tools

* Image Usage & Resolution